Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Azithromycin
Drug ID BADD_D00203
Description Azithromycin is a broad-spectrum macrolide antibiotic with a long half-life and a high degree of tissue penetration [A174172]. It was initially approved by the FDA in 1991 [A174175]. It is primarily used for the treatment of respiratory, enteric and genitourinary infections and may be used instead of other macrolides for some sexually transmitted and enteric infections. It is structurally related to erythromycin [A174169]. Azithromycin [9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin] is a part of the _azalide_ subclass of macrolides, and contains a 15-membered ring, with a methyl-substituted nitrogen instead of a carbonyl group at the 9a position on the aglycone ring, which allows for the prevention of its metabolism. This differentiates azithromycin from other types of macrolides [A174175]. In March 2020, a small study was funded by the French government to investigate the treatment of COVID-19 with a combination of azithromycin and the anti-malaria drug [hydroxychloroquine]. The results were positive, all patients taking the combination were virologically cured within 6 days of treatment, however, larger studies are required.[A192546]
Indications and Usage For the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions: H. influenzae, M. catarrhalis, S. pneumoniae, C. pneumoniae, M. pneumoniae, S. pyogenes, S. aureus, S. agal
Marketing Status Prescription; Discontinued
ATC Code J01FA10; S01AA26
DrugBank ID DB00207
KEGG ID D06390
MeSH ID D017963
PubChem ID 447043
TTD Drug ID D03HJK
NDC Product Code 53002-0470; 50111-787; 68071-2672; 70710-1458; 53002-5228; 68071-4795; 0781-5789; 68788-8125; 70518-2708; 50090-4720; 71610-001; 0409-0144; 50090-2509; 62332-251; 63629-8034; 68071-1528; 63629-7784; 63629-8251; 50090-4458; 68071-4773; 59651-008; 16571-695; 42806-147; 70710-1457; 59762-3051; 55150-174; 68788-7659; 71205-196; 50090-4721; 70518-0713; 68071-4902; 55700-731; 65862-641; 24658-706; 72189-314; 70518-2562; 50090-5376; 68071-4785; 63187-189; 76420-006; 0093-2027; 0781-5793; 53002-6221; 68071-4786; 53002-2230; 70518-3217; 71205-158; 70771-1424; 68071-4711; 71205-503; 50090-5283; 42291-082; 64679-961; 71205-645; 63187-169; 63187-594; 64679-964; 68788-8124; 65862-642; 42291-084; 55695-002; 71205-253; 70518-2433; 68788-7549; 68071-2507; 76420-213; 71205-519; 53002-2228; 68788-7066; 68071-4779; 63187-093; 63629-8311; 61294-9990; 59762-3130; 69306-250; 68071-4364; 42291-083; 0781-8089; 71610-381; 61919-555; 59651-007; 68071-2543; 53002-2225; 50090-5366; 68071-5035; 42806-151; 50111-788; 62332-253; 46708-253; 69452-173; 64679-962; 59762-3140; 70518-3254; 68071-2297; 45865-536; 60760-502; 68788-7598; 50090-0984; 63187-007; 59762-3120; 68071-5058; 68071-4812; 71335-1755; 69452-172; 71205-216; 68071-1527; 68788-7307; 68071-4774; 53002-2231; 68788-7507; 63187-622; 0093-2026; 71205-021; 50090-0983; 60760-808; 68071-5238; 43386-471; 42806-149; 71335-1252; 16571-696; 70710-1460; 50111-789; 53002-2224; 71205-424; 62756-512; 24658-708; 72189-088; 38779-2246; 59762-2198; 72189-087; 68071-5082; 59762-3110; 70518-0784; 55700-784; 42806-150; 69452-171; 50090-2491; 72189-093; 55700-852; 70710-1459; 0781-8090; 0781-8091; 68071-2266; 70771-1425; 46708-058; 53002-5221; 70518-3169; 70771-1422; 70518-0599; 53002-0473; 70771-1423; 65427-310; 68071-5170; 68071-2622; 53002-0472; 68071-2529; 71335-1195; 62332-252; 72189-015; 68788-7636; 63187-604; 68071-4255; 68071-4976; 46708-057; 55695-003; 71205-566; 43386-470
Synonyms Azithromycin | Azythromycin | Sumamed | Toraseptol | Vinzam | CP-62993 | CP 62993 | CP62993 | Zithromax | Azitrocin | Azadose | Ultreon | Zitromax | Azithromycin Dihydrate | Dihydrate, Azithromycin | Azithromycin Monohydrate | Monohydrate, Azithromycin | Goxal | Zentavion
Chemical Information
Molecular Formula C38H72N2O12
CAS Registry Number 83905-01-5
SMILES CCC1C(C(C(N(CC(CC(C(C(C(C(C(=O)O1)C)OC2CC(C(C(O2)C)O)(C)OC)C)OC3C(C(CC(O3)C)N(C) C)O)(C)O)C)C)C)O)(C)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Drug eruption23.03.05.001; 10.01.01.005; 08.01.06.0150.000050%Not Available
Drug hypersensitivity10.01.01.0010.006815%Not Available
Drug interaction08.06.03.001--Not Available
Dry eye06.08.02.0010.000139%
Dry mouth07.06.01.002--
Dysgeusia17.02.07.003; 07.14.03.001--
Dyspepsia07.01.02.0010.000050%
Dysphagia07.01.06.003--
Dyspnoea22.02.01.004; 02.01.03.0020.000366%
Dysuria20.02.02.002--
Ear infection11.01.05.001; 04.03.01.006--Not Available
Ear pain04.03.01.0030.000025%
Eczema23.03.04.006--
Electrocardiogram abnormal13.14.05.0010.000025%Not Available
Electrocardiogram QT prolonged13.14.05.0040.000076%
Enteritis07.08.03.002--
Eosinophil count increased13.01.06.004--Not Available
Eosinophilia01.02.04.0010.000050%
Eosinophilic pneumonia22.01.01.004; 01.02.04.0030.000025%Not Available
Epilepsy17.12.03.002--Not Available
Epistaxis24.07.01.005; 22.04.03.001--
Erythema23.03.06.0010.000151%Not Available
Erythema multiforme23.03.01.003; 10.01.03.0150.000025%
Extradural haematoma24.07.04.002; 17.08.05.001; 12.01.10.0020.000007%Not Available
Extravasation08.01.03.008--Not Available
Eye burns12.01.04.010; 06.11.01.0030.000025%Not Available
Eye discharge06.04.05.0010.000025%Not Available
Eye infection11.01.06.001; 06.04.05.0070.000025%
Eye irritation06.04.05.0030.000303%Not Available
Eye pain06.08.03.0020.000151%
The 4th Page    First    Pre   4 5 6 7 8    Next   Last    Total 12 Pages